• Publications
  • Influence
The development of a Clinician-Administered PTSD Scale
The Clinician-Administered PTSD Scale (CAPS-1) is a structured interview for assessing core and associated symptoms of PTSD and is intended for use by experienced clinicians, and also can be administered by appropriately trained paraprofessionals. Expand
The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability.
In a study involving four raters and 40 patients with obsessive-compulsive disorder at various stages of treatment, interrater reliability for the total Yale-Brown Scale score and each of the 10 individual items was excellent, with high degree of internal consistency among all item scores demonstrated with Cronbach's alpha coefficient. Expand
The Yale-Brown Obsessive Compulsive Scale. II. Validity.
Results from a previously reported placebo-controlled trial of fluvoxamine in 42 patients with obsessive-compulsive disorder showed that the Yale- Brown Scale was sensitive to drug-induced changes and that reductions in Yale-Brown Scale scores specifically reflected improvement in obsessive- compulsive disorder symptoms. Expand
Antidepressant effects of ketamine in depressed patients
A first placebo-controlled, double-blinded trial to assess the treatment effects of a single dose of an N-methyl-D-aspartate (NMDA) receptor antagonist in patients with depression suggests a potential role for NMDA receptor-modulating drugs in the treatment of depression. Expand
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Robust and rapid antidepressant effects resulted from a single intravenous dose of an N-methyl-D-aspartate antagonist; onset occurred within 2 hours postinfusion and continued to remain significant for 1 week. Expand
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
These data indicate that N-methyl-D-aspartate antagonists produce a broad range of symptoms, behaviors, and cognitive deficits that resemble aspects of endogenous psychoses, particularly schizophrenia and dissociative states. Expand
Psychobiological mechanisms of resilience and vulnerability: implications for successful adaptation to extreme stress.
  • D. Charney
  • Medicine, Psychology
  • The American journal of psychiatry
  • 1 February 2004
An integrative model of resilience and vulnerability that encompasses the neurochemical response patterns to acute stress and the neural mechanisms mediating reward, fear conditioning and extinction, and social behavior is proposed. Expand
Measurement of Dissociative States with the Clinician-Administered Dissociative States Scale (CADSS)
Initial analyses indicated good interrater reliability and construct validity and sensitivity of the CADSS to discriminate patients with dissociative disorders from patients with other psychiatric disorders and healthy subjects. Expand
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Ketamine demonstrated rapid antidepressant effects in an optimized study design, further supporting NMDA receptor modulation as a novel mechanism for accelerated improvement in severe and chronic forms of depression. Expand